# Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

> **NCT04385589** · PHASE4 · COMPLETED · sponsor: **Assiut University** · enrollment: 100 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** insulin

## Key facts

- **NCT ID:** NCT04385589
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2020-12-15
- **Final completion:** 2020-12-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385589, "Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04385589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*